Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.

  title={Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent.},
  author={Mary Hodges and J M Haugland and G A Granrud and G. J. Conard and Richard W. Asinger and Frank L Mikell and Jan Krejci},
  volume={65 5},
Flecainide acetate, a new antiarrhythmic agent, was given orally to 11 hospitalized patients with chronic high-frequency ventricular ectopic depolarizations. Drug effectiveness was evaluated with a dose-ranging single-blind protocol, which included placebo control and washout periods. Twice-daily dosing (average daily dose 436 mg) completely suppressed all ventricular ectopic activity in five of 11 patients; average suppression in the 11 patients was 96.3%. Complex ventricular arrhythmias… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 21 extracted citations

Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibres

Naunyn-Schmiedeberg's Archives of Pharmacology • 1990
View 1 Excerpt
Highly Influenced

Philosophers on drugs

Synthese • 2017
View 2 Excerpts

Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology • 2011


Publications referenced by this paper.
Showing 1-10 of 27 references

Human plasma pharmacokinetics of flecainide acetate ( R - 818 ) , a new antiarrhythmic , following single oral and intravenous doses

GJ Conard, GL Carlson, JW Frost, RE Ober
Clin Pharmacol Ther • 1979

Similar Papers

Loading similar papers…